Skip to content
Markets News
Earnings1 min read

BioNTech Returns to Profit as 2026 Revenue Range Rises

Makkler Newsroom
November 3, 2026 · Based on reporting by GlobeNewswire, finanzen.net, Anadolu Ajansı

The company reported third-quarter net profit of €184.5 million and lifted its full-year revenue target despite lower sales.

Key takeaways

  • BioNTech posted €184.5 million in third-quarter net profit, compared with a loss a year earlier.
  • Quarterly revenue fell to €1.29 billion from €1.52 billion.
  • The company raised its 2026 revenue target range to €1.7 billion to €1.9 billion.
  • Third-quarter research and development spending rose to €748.1 million.

BioNTech returned to profit in the third quarter, reporting net income of €184.5 million for July through September. A year earlier, it recorded a net loss of €28.7 million.

Earnings per share increased to €0.73 from €0.12. The company’s return to profit was mainly due to large one-off expenses tied to lawsuits and legal disputes not recurring this year, according to the reports.

Revenue fell to €1.29 billion from €1.52 billion a year earlier as global demand for COVID-19 vaccines continued to decline. BioNTech nevertheless raised its 2026 revenue target range to €1.7 billion to €1.9 billion, lifting the lower end from at least €1.6 billion.

The company said it was accelerating its shift toward cancer medicines as it seeks to reduce its dependence on the shrinking COVID-19 vaccine market. It aims to bring more than one oncology product to market by 2030.

Research and development expenses rose to €748.1 million in the quarter, from €564.8 million a year earlier, amid the strategic shift and ongoing clinical studies. As of Tuesday afternoon, BioNTech shares traded at $87.56, up 0.03% since the previous close.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.